Incretin Based Therapy and Pancreatic Cancer: Realising the Reality

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Aug 18

PMID 35978867

Authors

Varun Suryadevara

Ayan Roy

Jayaprakash Sahoo

Sadishkumar Kamalanathan

Dukhabandhu Naik

Pazhanivel Mohan

Raja Kalayarasan

Affiliations

Soon will be listed here.

Abstract

Incretin-based therapies like glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help maintain the glycaemic control in patients with type 2 diabetes mellitus with additional systemic benefits and little risk of hypoglycaemia. These medications are associated with low-grade chronic pancreatitis in animal models inconsistently. The incidence of acute pancreatitis was also reported in some human studies. This inflammation provides fertile ground for developing pancreatic carcinoma (PC). Although the data from clinical trials and population-based studies have established safety regarding PC, the pathophysiological possibility that low-grade chronic pancreatitis leads to PC remains. We review the existing literature and describe the relationship between incretin-based therapies and PC.

Citing Articles

A Specific Collagen Hydrolysate Improves Postprandial Glucose Tolerance in Normoglycemic and Prediabetic Mice and in a First Proof of Concept Study in Healthy, Normoglycemic and Prediabetic Humans.

Grasset E, Briand F, Virgilio N, Schon C, Wilhelm M, Cudennec B Food Sci Nutr. 2024; 12(11):9607-9620.

PMID: 39619994 PMC: 11606891. DOI: 10.1002/fsn3.4538.

The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.

Ayoub M, Faris C, Juranovic T, Chela H, Daglilar E Cancers (Basel). 2024; 16(9).

PMID: 38730578 PMC: 11082986. DOI: 10.3390/cancers16091625.

Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment.

Cuttica C, Briata I, DeCensi A Nutrients. 2023; 15(17).

PMID: 37686769 PMC: 10490004. DOI: 10.3390/nu15173737.

References

Zambirinis C, Pushalkar S, Saxena D, Miller G . Pancreatic cancer, inflammation, and microbiome. Cancer J. 2014; 20(3):195-202. PMC: 4112373. DOI: 10.1097/PPO.0000000000000045. View

Parker V, Robertson D, Wang T, Hornigold D, Petrone M, Cooper A . Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. J Clin Endocrinol Metab. 2019; 105(3). DOI: 10.1210/clinem/dgz047. View

Perfetti R, Zhou J, Doyle M, Egan J . Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000; 141(12):4600-5. DOI: 10.1210/endo.141.12.7806. View

Azoulay L, Filion K, Platt R, Dahl M, Dormuth C, Clemens K . Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016; 352:i581. PMC: 4772785. DOI: 10.1136/bmj.i581. View

Egan A, Blind E, Dunder K, de Graeff P, Hummer B, Bourcier T . Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med. 2014; 370(9):794-7. DOI: 10.1056/NEJMp1314078. View

Alves C, Batel-Marques F, Macedo A . A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012; 98(2):271-84. DOI: 10.1016/j.diabres.2012.09.008. View

Barreira da Silva R, Laird M, Yatim N, Fiette L, Ingersoll M, Albert M . Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol. 2015; 16(8):850-8. DOI: 10.1038/ni.3201. View

Chen H, Zhou X, Chen T, Liu B, Jin W, Gu H . Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials. Diabetes Ther. 2016; 7(4):725-742. PMC: 5118236. DOI: 10.1007/s13300-016-0198-3. View

Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, Kalayarasan R . Diabetes and pancreatic cancer: Exploring the two-way traffic. World J Gastroenterol. 2021; 27(30):4939-4962. PMC: 8384733. DOI: 10.3748/wjg.v27.i30.4939. View

10.

Mendez-Bailon M, de Miguel Yanes J, Jimenez-Garcia R, Hernandez-Barrera V, Perez-Farinos N, Lopez-de-Andres A . National trends in incidence and outcomes of acute pancreatitis among type 2 diabetics and non-diabetics in Spain (2001-2011). Pancreatology. 2014; 15(1):64-70. DOI: 10.1016/j.pan.2014.11.004. View

11.

Bonner-Weir S, Int Veld P, Weir G . Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes Metab. 2014; 16(7):661-6. PMC: 5678976. DOI: 10.1111/dom.12257. View

12.

Montvida O, Green J, Atherton J, Paul S . Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. Diabet Med. 2018; 36(4):491-498. DOI: 10.1111/dme.13835. View

13.

Butler P, Elashoff M, Elashoff R, Gale E . A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?. Diabetes Care. 2013; 36(7):2118-25. PMC: 3687282. DOI: 10.2337/dc12-2713. View

14.

Nauck M . The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. Metabolism. 2019; 103:154031. DOI: 10.1016/j.metabol.2019.154031. View

15.

Butler A, Campbell-Thompson M, Gurlo T, Dawson D, Atkinson M, Butler P . Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013; 62(7):2595-604. PMC: 3712065. DOI: 10.2337/db12-1686. View

16.

Nagel A, Ahmed-Sarwar N, Werner P, Cipriano G, Van Manen R, Brown J . Dipeptidyl Peptidase-4 Inhibitor-Associated Pancreatic Carcinoma: A Review of the FAERS Database. Ann Pharmacother. 2015; 50(1):27-31. DOI: 10.1177/1060028015610123. View

17.

Frias J, Davies M, Rosenstock J, Perez Manghi F, Lando L, Bergman B . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515. DOI: 10.1056/NEJMoa2107519. View

18.

Abd El Aziz M, Cahyadi O, Meier J, Schmidt W, Nauck M . Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2019; 22(4):699-704. DOI: 10.1111/dom.13924. View

19.

Pasca di Magliano M, Logsdon C . Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013; 144(6):1220-9. PMC: 3902845. DOI: 10.1053/j.gastro.2013.01.071. View

20.

Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W . Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol. 2017; 16(1):31. PMC: 5333444. DOI: 10.1186/s12933-017-0512-z. View